Last reviewed · How we verify

Felmetatug Vedotin — Competitive Intelligence Brief

Felmetatug Vedotin (felmetatug-vedotin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Given into the vein (IV; intravenously). Area: Oncology.

discontinued Given into the vein (IV; intravenously) Oncology Live · refreshed every 30 min

Target snapshot

Felmetatug Vedotin (felmetatug-vedotin) — Pfizer Inc.. Given into the vein (IV; intravenously)

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Felmetatug Vedotin TARGET felmetatug-vedotin Pfizer Inc. discontinued Given into the vein (IV; intravenously)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Given into the vein (IV; intravenously) class)

  1. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Felmetatug Vedotin — Competitive Intelligence Brief. https://druglandscape.com/ci/felmetatug-vedotin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: